Understanding how EZH2 and PARP inhibitors work in prostate cancer treatment
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate Cancer
This study is looking at how a protein called EZH2 affects the way castration-resistant prostate cancer responds to treatments, and it aims to find better ways to combine therapies for patients like you to improve treatment outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10916201 on NIH RePORTER |
What this research studies
This research investigates the role of EZH2, a protein that can influence cancer treatment resistance in castration-resistant prostate cancer (CRPC). The team aims to explore how EZH2 interacts with DNA repair processes and how this interaction affects the effectiveness of EZH2 and PARP inhibitors. By conducting both preclinical and clinical studies, they will assess the biological and clinical impacts of combining these therapies, tailoring approaches based on individual patient characteristics. This research could lead to more effective treatment strategies for patients with CRPC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with castration-resistant prostate cancer who may benefit from novel treatment approaches.
Not a fit: Patients with early-stage prostate cancer or those not resistant to standard treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new combination therapies that improve treatment outcomes for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results with similar combination therapies in other cancer types, suggesting potential for success in this area as well.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Beltran, Himisha — Dana-Farber Cancer Inst
- Study coordinator: Beltran, Himisha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.